PA8583001A1 - Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b - Google Patents

Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b

Info

Publication number
PA8583001A1
PA8583001A1 PA20038583001A PA8583001A PA8583001A1 PA 8583001 A1 PA8583001 A1 PA 8583001A1 PA 20038583001 A PA20038583001 A PA 20038583001A PA 8583001 A PA8583001 A PA 8583001A PA 8583001 A1 PA8583001 A1 PA 8583001A1
Authority
PA
Panama
Prior art keywords
derivatives
pirrolidino
bencil
fenil
eter
Prior art date
Application number
PA20038583001A
Other languages
English (en)
Inventor
Rene Wyler
Andrew William Thomas
Jolidon Synese
Wolfgang Wostl
Rosa Maria Rodriguez-Sarmiento
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8583001A1 publication Critical patent/PA8583001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

DERIVADOS 4 - PIRROLIDINO RACEMICA O ENANTIOMERICAMENTE PUROS, PROCESOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHOS DERIVADOS, Y SU USO EN LA PREVENCION Y TRATAMIENTO DE ENFERMEDADES, POR EJEMPLO QUE ESTAN MEDIADAS POR INHIBIDORES DE MONOAMINO OXIDASA B, EN PARTICULAR ENFERMEDAD DE ALZHEIMER O DEMENCIA SENIL.
PA20038583001A 2002-09-20 2003-09-17 Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b PA8583001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20

Publications (1)

Publication Number Publication Date
PA8583001A1 true PA8583001A1 (es) 2004-04-23

Family

ID=32010924

Family Applications (3)

Application Number Title Priority Date Filing Date
PA20038583001A PA8583001A1 (es) 2002-09-20 2003-09-17 Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
PA20038583501A PA8583501A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob
PA20038583601A PA8583601A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob

Family Applications After (2)

Application Number Title Priority Date Filing Date
PA20038583501A PA8583501A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob
PA20038583601A PA8583601A1 (es) 2002-09-20 2003-09-18 Derivados de pirrolidona como inhibidores de maob

Country Status (32)

Country Link
US (4) US7235581B2 (es)
EP (3) EP1542971A1 (es)
JP (3) JP4335140B2 (es)
KR (3) KR100676014B1 (es)
CN (3) CN100383118C (es)
AR (3) AR041298A1 (es)
AT (2) ATE459601T1 (es)
AU (3) AU2003267381B2 (es)
BR (4) BRPI0314631B1 (es)
CA (3) CA2498785C (es)
CY (1) CY1110745T1 (es)
DE (2) DE60333202D1 (es)
DK (1) DK1542970T3 (es)
ES (2) ES2338646T3 (es)
GT (3) GT200300205A (es)
HK (3) HK1083498A1 (es)
HR (3) HRP20050263B1 (es)
JO (2) JO2604B1 (es)
MX (3) MXPA05002878A (es)
MY (3) MY134480A (es)
NO (3) NO330012B1 (es)
NZ (3) NZ538049A (es)
PA (3) PA8583001A1 (es)
PE (3) PE20050077A1 (es)
PL (3) PL376019A1 (es)
PT (1) PT1542970E (es)
RU (3) RU2336268C2 (es)
SI (1) SI1542970T1 (es)
TW (3) TWI286132B (es)
UY (3) UY27991A1 (es)
WO (3) WO2004026827A1 (es)
ZA (3) ZA200501137B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY134480A (en) * 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
GB0314373D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
AU2005268894B2 (en) * 2004-08-02 2010-12-16 F. Hoffmann-La Roche Ag Benzyloxy derivatives as MAOB inhibitors
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
MX2007011154A (es) * 2005-03-15 2007-10-17 Hoffmann La Roche Metodo para preparar derivados de eter 4-pirrolidinofenilbencilico enantiomericamente puros.
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
JP5139307B2 (ja) * 2005-10-10 2013-02-06 グラクソ グループ リミテッド ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
CA2706017A1 (en) * 2007-03-30 2008-10-09 Jorge R. Barrio In vivo imaging of sulfotransferases
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
WO2014158916A1 (en) 2013-03-14 2014-10-02 Dart Neuroscience, Llc Substituted naphthyridine and quinoline compounds as mao inhibitors
CZ305213B6 (cs) * 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
RU2016118748A (ru) * 2013-10-29 2017-12-05 Ф. Хоффманн-Ля Рош Аг Кристаллические формы производного пирролидона, полезные при лечении болезни альцгеймера, и их получение
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
WO2016156124A1 (en) 2015-03-27 2016-10-06 F. Hoffmann-La Roche Ag Pharmaceutical formulation comprising sembragiline
WO2019065794A1 (ja) 2017-09-27 2019-04-04 国立大学法人鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた鎮痛薬
AU2018346763A1 (en) 2017-10-05 2020-04-16 Biogen Inc. Process for preparing alpha-carboxamide pyrolidine derivatives
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
EP3762364B1 (en) 2018-03-08 2023-08-23 Sunshine Lake Pharma Co., Ltd. Pyrrolidineamide derivatives and uses thereof
EP3932490A4 (en) 2019-02-27 2022-11-16 Kagoshima University ANTIPRURIC AGENT USING PAC1 RECEPTOR ANTAGONISTS
JP7049637B1 (ja) 2020-05-08 2022-04-07 国立大学法人 鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた抗うつ・抗不安薬
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
EP0393607B1 (en) 1989-04-19 1996-02-21 Otsuka Pharmaceutical Co., Ltd. Phenylcarboxylic acid derivatives having a hetero ring
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
JP3258027B2 (ja) 1996-03-15 2002-02-18 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレジリン投与による末梢ニューロパシーの予防および治療方法
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
EP1165546A2 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
AU1359801A (en) 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
WO2001058388A1 (en) * 2000-02-10 2001-08-16 Potencia Medical Ag Urinary incontinence treatment with wireless energy supply
ATE296071T1 (de) * 2000-02-14 2005-06-15 Potencia Medical Ag Penisprothese
MY134480A (en) * 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism

Also Published As

Publication number Publication date
HK1083498A1 (en) 2006-07-07
US20060122235A1 (en) 2006-06-08
PT1542970E (pt) 2010-07-19
MY135696A (en) 2008-06-30
NO20050665L (no) 2005-04-18
US20040116707A1 (en) 2004-06-17
EP1542970B1 (en) 2010-06-30
GT200300206A (es) 2004-04-29
AU2003273901B2 (en) 2008-07-10
MXPA05002878A (es) 2005-05-27
ES2338646T3 (es) 2010-05-11
US20040106650A1 (en) 2004-06-03
RU2336267C2 (ru) 2008-10-20
CN1681778A (zh) 2005-10-12
BRPI0314631B1 (pt) 2018-04-17
AR041299A1 (es) 2005-05-11
AR041297A1 (es) 2005-05-11
CA2496756A1 (en) 2004-04-01
PE20050078A1 (es) 2005-02-28
RU2005111969A (ru) 2006-01-20
JP2006510596A (ja) 2006-03-30
NZ538046A (en) 2007-08-31
CA2498785C (en) 2011-07-26
RU2005111974A (ru) 2006-01-20
US7122562B2 (en) 2006-10-17
ZA200501137B (en) 2006-12-27
CA2498785A1 (en) 2004-04-01
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
HRP20050263B1 (hr) 2013-09-30
RU2005111968A (ru) 2006-11-10
BR0314314A (pt) 2005-07-26
PA8583601A1 (es) 2004-09-16
PL376019A1 (en) 2005-12-12
ES2344557T3 (es) 2010-08-31
DK1542970T3 (da) 2010-08-02
AU2003270213B2 (en) 2009-02-12
NZ538048A (en) 2007-05-31
PL376021A1 (en) 2005-12-12
CN100503562C (zh) 2009-06-24
AU2003270213B8 (en) 2009-03-05
JP4335142B2 (ja) 2009-09-30
TW200413350A (en) 2004-08-01
NO20050652L (no) 2005-03-08
NO20050701L (no) 2005-03-02
PA8583501A1 (es) 2004-04-23
KR100681586B1 (ko) 2007-02-09
TW200408624A (en) 2004-06-01
DE60331559D1 (de) 2010-04-15
PE20050079A1 (es) 2005-03-01
AU2003273901A1 (en) 2004-04-08
UY27993A1 (es) 2004-03-31
EP1542969B1 (en) 2010-03-03
EP1542970A1 (en) 2005-06-22
UY27990A1 (es) 2004-03-31
JO2604B1 (en) 2011-11-01
JP2006503834A (ja) 2006-02-02
UY27991A1 (es) 2004-03-31
ZA200501557B (en) 2005-09-08
HRP20050263A2 (en) 2006-12-31
EP1542969A1 (en) 2005-06-22
WO2004026826A1 (en) 2004-04-01
ZA200501311B (en) 2006-10-25
CY1110745T1 (el) 2015-06-10
GT200300205A (es) 2004-04-29
ATE472530T1 (de) 2010-07-15
CN100383118C (zh) 2008-04-23
BR0314631A (pt) 2005-08-02
KR20050057450A (ko) 2005-06-16
MXPA05002880A (es) 2005-05-27
TWI337604B (en) 2011-02-21
US7151111B2 (en) 2006-12-19
AU2003267381B2 (en) 2009-08-27
KR100676015B1 (ko) 2007-01-30
CA2498335A1 (en) 2004-04-01
JP2006503833A (ja) 2006-02-02
AU2003270213A1 (en) 2004-04-08
CN1681779A (zh) 2005-10-12
SI1542970T1 (sl) 2010-08-31
CN1681777A (zh) 2005-10-12
US20040097578A1 (en) 2004-05-20
AR041298A1 (es) 2005-05-11
KR100676014B1 (ko) 2007-01-30
WO2004026827A1 (en) 2004-04-01
NO329754B1 (no) 2010-12-13
NO330012B1 (no) 2011-02-07
WO2004026825A1 (en) 2004-04-01
JO2605B1 (en) 2011-11-01
TWI286132B (en) 2007-09-01
KR20050057456A (ko) 2005-06-16
KR20050057466A (ko) 2005-06-16
HRP20050262A2 (en) 2006-06-30
GT200300204A (es) 2004-04-29
NZ538049A (en) 2007-05-31
CN100400509C (zh) 2008-07-09
MY134480A (en) 2007-12-31
HK1083499A1 (en) 2006-07-07
TW200410935A (en) 2004-07-01
ATE459601T1 (de) 2010-03-15
TWI331994B (en) 2010-10-21
JP4335141B2 (ja) 2009-09-30
US7037935B2 (en) 2006-05-02
EP1542971A1 (en) 2005-06-22
RU2323209C2 (ru) 2008-04-27
MY133332A (en) 2007-11-30
AU2003267381A1 (en) 2004-04-08
US7235581B2 (en) 2007-06-26
DE60333202D1 (de) 2010-08-12
CA2496756C (en) 2012-01-10
JP4335140B2 (ja) 2009-09-30
PL376018A1 (en) 2005-12-12
BR0314299A (pt) 2005-12-13
PE20050077A1 (es) 2005-03-01
RU2336268C2 (ru) 2008-10-20
HRP20050261A2 (en) 2006-05-31
HK1084383A1 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
PA8583001A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
MX2009012177A (es) Moduladores de gamma-secretasa.
MX2010001506A (es) Moduladores de gamma secretasa.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
CR8778A (es) Revestimientos de azucar y metodos para estos
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
BRPI0619153A8 (pt) derivados de 4-aminopirroltriazina substituída, e composição farmacêutica
GT200600258A (es) Derivados de n-(piridin-2-il)-sulfonamida
BRPI0517088A (pt) formulação de comprimido estável
WO2006124748A3 (en) Multicyclic compounds and methods of their use
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
ATE417607T1 (de) Sphingolipide gegen krankhafte prozesse in lipid rafts
BRPI0607330A2 (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto
WO2008153793A3 (en) Gamma secretase modulators
BRPI0510719A (pt) derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
DK1778623T3 (da) Derivater af 1-phenylalkancarboxylsyrer til behandling af neurodegenerative sygdomme
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
UY29631A1 (es) Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica